OPTH — Optimi Health Corp.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2027329 ·
Last close
$2.10
Market Cap
$12.02M
52W High
$6.40
52W Low
$1.90
ADV30
36,861
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 140,200 66,623 -2,134,695 -2,404,430 25,861,164 13,073,333 8,223,125
Mar 2026 99,500 89,464 -1,356,912 -1,591,871 13,509,676 106,711 9,971,230
Dec 2025 0 0 -1,280,597 -1,553,975 14,236,203 491,750 9,219,190
Sep 2025 -64,029 -464,233 -1,667,227 -1,349,367 15,212,645 1,145,065 8,641,984

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,205,981
Investing CF
$-88,411
Financing CF
$3,345,389
CapEx
$-88,411
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-08-20

Balance + Analyst (yfinance extras)

Retained Earnings
$-29,853,753
Inventory
$300,352
Receivables
$44,128
ST Investments
—
EBIT TTM
$-4,574,734
Pretax Income TTM
$-5,402,531
Interest Exp TTM
$827,797
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$175,671
EBITDA
$-4,207,583
Free Cash Flow
$-1,725,642
Enterprise Value
$17,379,542
Total Cash
$13,073,333
Total Debt
$5,144,542
Shares Out
5,725,867
Trailing EPS
$-1.46
Book Value
$2.23
ROE
-54.4%
ROA
-16.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 426,301 -4,612,279 -3,712,031 15,212,645 8,641,984 6,570,661 -2,627,901
Sep 2024 389,850 -5,609,185 -6,035,859 14,551,035 4,975,323 9,575,712 -4,281,693
Sep 2023 181,087 -5,272,295 -5,194,548 16,491,729 3,280,836 13,210,893 -3,601,537
Sep 2022 80,717 -7,389,778 -7,350,828 16,817,771 797,665 16,020,106 -4,579,541

Peers — same industry

TickerNameMarket CapLastDaily %
CMMB Chemomab Therapeutics Ltd. $12.02M $1.64 —
NEUP Neuphoria Therapeutics Inc. $12.27M $2.27 —
ASBP Aspire-Lakewood Holdings, Inc. $11.64M $8.30 —
MTNB Matinas BioPharma Holdings, Inc. $12.57M $0.86 —
LSTA LISATA THERAPEUTICS, INC. $11.24M $1.04 —

News headlines (Yahoo Finance, 1h cache)

Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement
2026-11-18 12:30 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-11-08 20:56 · Yahoo
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
2026-10-26 12:00 · Yahoo
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
2026-10-20 12:30 · Yahoo
Optimi Health to Present at the ThinkEquity Conference
2026-10-07 13:00 · Yahoo
Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial
2026-09-23 15:58 · Yahoo
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
2026-09-23 13:00 · Yahoo
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
2026-09-22 13:00 · Yahoo
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
2026-09-19 00:30 · Yahoo
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
2026-09-10 12:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.